1. P123 Inhaled corticosteroid plus long-acting β2-agonist therapy is overused in the treatment of patients with chronic obstructive pulmonary disease: post hoc analyses of two 1-year studies. (12th November 2015) Authors: Watz, H; Ferguson, GT; Grönke, L; Voß, F; Abrahams, R; Buhl, R Journal: Thorax Issue: Volume 70(2015)Supplement 3 Page Start: A137 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P294 Benefits of tiotropium/olodaterol over tiotropium at delaying clinically significant events in patients with copd classified as gold B. (15th November 2016) Authors: Buhl, R; McGarvey, L; Korn, S; Ferguson, GT; Grönke, L; Hallmann, C; Voß, F; Rabe, KF; Maltais, F Journal: Thorax Issue: Volume 71(2016)Supplement 3 Page Start: A251 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P295 Efficacy and safety of tiotropium/olodaterol in patients with copd by ats category. (15th November 2016) Authors: Maltais, F; Pizzichini, E; Grönke, L; Voß, F; Derom, E Journal: Thorax Issue: Volume 71(2016)Supplement 3 Page Start: A252 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P296 Effect of tiotropium/olodaterol therapy on copd exacerbations in the tonado® studies. (15th November 2016) Authors: Derom, E; Fležar, M; Grönke, L; Voß, F; Buhl, R Journal: Thorax Issue: Volume 71(2016)Supplement 3 Page Start: A253 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P298 Tiotropium/olodaterol therapy provides symptomatic benefits irrespective of prior maintenance treatment: post hoc analyses of the otemto® studies. (15th November 2016) Authors: Abrahams, R; Ferguson, GT; Bjermer, L; Grönke, L; Voß, F; Singh, D Journal: Thorax Issue: Volume 71(2016)Supplement 3 Page Start: A255 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P299 Effects of symptom severity at baseline on lung-function and sgrq responses in the otemto® studies. (15th November 2016) Authors: Martinez, FJ; Abrahams, R; Ferguson, GT; Bjermer, L; Grönke, L; Voß, F; Singh, D Journal: Thorax Issue: Volume 71(2016)Supplement 3 Page Start: A255 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P55 Benefits of tiotropium/olodaterol on symptoms and health-related quality of life in patients with moderate to severe COPD with chronic bronchitis and/or emphysema. (15th November 2016) Authors: Ferguson, GT; Abrahams, R; Bjermer, L; Grönke, L; Voß, F; Singh, D Journal: Thorax Issue: Volume 71(2016)Supplement 3 Page Start: A113 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. S102 Eosinophil counts as a predictor of future COPD exacerbations in the DYNAGITO trial. (12th November 2019) Authors: Calverley, PMA; Jenkins, C; Wedzicha, JA; de la Hoz, A; Voß, F; Rabe, KF; Anzueto, A Journal: Thorax Issue: Volume 74(2019)Supplement 2 Page Start: A64 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. S29 The impact of GOLD stage on the effectiveness of tiotropium/olodaterol in preventing COPD exacerbations in the DYNAGITO trial. (12th November 2019) Authors: Wedzicha, J; Calverley, PMA; Anzueto, AR; de la Hoz, A; Voß, F; Rabe, KF; Jenkins, C Journal: Thorax Issue: Volume 74(2019)Supplement 2 Page Start: A19 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗